Arcturus therapeutics holdings inc. expands platform with starr technology™

Arcturus therapeutics announced that the company is expanding its platform to include starr (self-transcribing and replicating rna) technology™ for human and animal health vaccine applications. the starr technology™ platform combines self-replicating rna with lunar®, a leading nanoparticle delivery system, into a single solution for partners. starr technology™ is delivered into the cell to generate a protective immune response or drive therapeutic protein expression to potentially prevent against or treat a variety of diseases. the self-replicating rna-based therapeutic vaccine triggers rapid and immediate antigen expression within host cells and a stronger t-cell response. this combination is expected to provide longer-lasting rna, lowering dose requirements compared to traditional rna-based vaccines.
ARCT Ratings Summary
ARCT Quant Ranking